2019•PubMedRequires access

[The three-monthly paliperidone palmitate depot in the treatment of schizophrenia].

Symen K. Spoelstra, Leonie Bais, H. Knegtering

Abstract

BACKGROUND: A three-monthly formulation of intramuscular paliperidone palmitate has been available on the Dutch and Belgian markets since 2016. AIM: To provide an overview of the indication, effectiveness and side-effects of this injectable three-monthly formulation of paliperidone and to offer considerations for clinical practice. METHOD: A clinically-oriented literature study. RESULTS: Three-monthly paliperidone palmitate depot appears to be as effective as the monthly paliperidone depot and has the same profile of side-effects. CONCLUSION: Three-monthly paliperidone palmitate is an effective treatment option for schizophrenia. However, future research and clinical practice need to clarify the position of this depot in the treatment trajectory.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Paliperidone Palmitate, Paliperidone, Schizophrenia (object-oriented programming), Medicine, Depot, Extended release, Psychiatry, Pharmacology